首页>
外国专利>
A human or Humanized Antibody, or a fragment thereof with an Antigen binding region that is specific to direct the Protein to the Receptor of Human thymic stromal limfoproteina (htslpr)
A human or Humanized Antibody, or a fragment thereof with an Antigen binding region that is specific to direct the Protein to the Receptor of Human thymic stromal limfoproteina (htslpr)
1. - an isolated portion of an Antibody or Antigen of the same link, which comprises a sequence of the variable region of heavy chain of SEQ ID no: 7 or the SEQ ID no: 21. 2.- isolated an Antibody or a portion of the same Antigen Link, which comprises a sequence of the variable region of heavy chain of SEQ ID no: 7, and a sequence of the variable region of light chain of SEQ ID no: 8, or a sequence of the variable region of heavy chain The SEQ ID no: 21, and a sequence of the variable region of light chain of SEQ ID no: 22. 3.The Antibody of claim 2, which includes cdrh1, H2 and H3 of SEQ ID: 1, 2, and 3, respectively, of SEQ ID Nos: 15, 16, and 17, respectively, or a sequence of cdrl1, L2 and L3 of SEQ ID Nos: 4 5 and 6, respectively, of SEQ ID Nos: 18, 19 and 20, respectively Mind. 4.The Antibody of claim 2, which includes the cdrh1, H2 and H3 of SEQ ID: 1, 2, and 3, respectively, of SEQ ID Nos: 15, 16, and 17, respectively, and a sequence of cdrl1, L2, and L3 of SEQ ID Nos: 4, 5, and 6, respectively, of the SEQ ID no: 18, 19 and 20, respec Ly. 5.The Antibody of claim 2, which comprises an amino acid sequence of the variable region of heavy chain is at least 80 percent identical to SEQ ID no: 7, and an amino acid sequence of the variable region of light chain is at least 80 Ci This is identical to the SEQ ID no: 8Or comprising an amino acid sequence of the variable region of heavy chain is at least 80 percent identical to SEQ ID no: 21, and an amino acid sequence of the variable region of light chain is at least 80 percent identical to SEQ ID no: 22. The Antibody of claim 2, which is a Chimeric Antibody.
展开▼
机译:1.-同一链的抗体或抗原的分离部分,其包含SEQ ID NO:7或SEQ ID NO:21的重链可变区的序列。2.-分离的抗体或部分相同抗原链的序列,其包含SEQ ID NO:7的重链可变区的序列和SEQ ID NO:8的轻链的可变区的序列或重链的可变区的序列3.权利要求2的抗体,其包括SEQ ID NO:21的轻链的可变区的序列,以及SEQ ID NO:22的轻链的可变区的序列。3.抗体,其包括SEQ ID NO:1、2和3的cdrh1,H2和H3。分别是SEQ ID Nos:15、16和17的分别,或者分别是SEQ ID Nos:18、19和20的cdrl1,L2和L3的序列心神。 4.权利要求2的抗体,其分别包括SEQ ID No:15、16和17的SEQ ID:1、2和3的cdrh1,H2和H3,以及cdrl1,L2的序列。 SEQ ID No:18、19和20的SEQ ID Nos:4、5和6的L1和L3分别针对Ly。 5.权利要求2的抗体,其包含重链可变区的氨基酸序列与SEQ ID no:7至少80%相同,并且轻链可变区的氨基酸序列至少80。 Ci这与SEQ ID no:8相同或包含重链可变区的氨基酸序列与SEQ ID no:21至少80%相同,并且轻链可变区的氨基酸序列位于25.与SEQ ID no:22具有至少80%的同一性。权利要求2的抗体,其是嵌合抗体。
展开▼